New and amended listings on the National Immunisation Program (NIP).
The Government will provide funding of $449.4 million over 5 years from 2022-23 (and $118.0 million ongoing) and deliver efficiencies of $74.1 million over 4 years from 2023-24 (and $18.1 million ongoing) for new and amended listings on the National Immunisation Program (NIP). Funding of $446.5 million over 5 years from 2022-23 (and $117.7 million ongoing) will be provided for Shingrix to replace Zostavax on the NIP for the prevention of herpes zoster virus (shingles) in a wider range of eligible patients. From 1 July 2023, Gardasil9, for the prevention of Human Papillomavirus, will be available to eligible patients up to the age of 25. The recommended dose schedule for some patients will reduce from 2 to one, resulting in efficiencies of $71.2 million over 5 years (and $17.8 million ongoing).